2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal Of Cancer 2023, 186: 172-184. PMID: 37086595, PMCID: PMC11003310, DOI: 10.1016/j.ejca.2023.03.015.Peer-Reviewed Original ResearchConceptsAdvanced endometrial cancerEndometrial cancerWeek 12Life QuestionnaireDefinitive deteriorationFunctional scalesPhysician's choiceGlobal health status/qualityFavorable benefit/risk profileHealth status/qualityBenefit/risk profileEuroQol-5 DimensionsHealth-related qualityTreatment of patientsTingling/numbnessImpact of treatmentQuality of lifeRate of completionHRQOL endpointsAppetite lossPoor body imageCancer QualityLife scoresMuscular painSafety results
2019
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
Wallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. BMC Medicine 2019, 17: 117. PMID: 31203816, PMCID: PMC6572730, DOI: 10.1186/s12916-019-1344-3.Peer-Reviewed Original ResearchConceptsNew clinical trialsClinical trialsPostmarketing commitmentFDA approvalPeer-reviewed journalsNovel drugsPharmaceutical companiesCross-sectional analysisRate of completionRates of registrationClinical studiesPublic reporting requirementsFirst approvalTherapeutic evaluationUS FoodDrug AdministrationTrialsNew drugsFDA documentsBiologicsFDADrugsFDA recordsApprovalStatus
2016
Prenatal care in a specialized diabetes in pregnancy program improves compliance with postpartum testing in GDM women*
Huynh T, Ghaffari N, Bastek J, Durnwald C. Prenatal care in a specialized diabetes in pregnancy program improves compliance with postpartum testing in GDM women*. The Journal Of Maternal-Fetal & Neonatal Medicine 2016, 30: 1075-1079. PMID: 27296556, DOI: 10.1080/14767058.2016.1201472.Peer-Reviewed Original ResearchConceptsGDM womenPrenatal carePregnancy programPregnancy clinicOral glucose tolerance testRetrospective cohort studyGlucose tolerance testUniversity Health SystemRate of completionTime trend analysisPostpartum testingPostpartum visitClinical characteristicsCohort studyPrimary outcomePotential confoundersPrenatal clinicsTolerance testPostpartum periodDiabetesHealth systemClinicCareWomenSecular trends
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply